New MRI dye could spot brain tumors sooner in cancer patients
NCT ID NCT07492121
First seen Mar 30, 2026 · Last updated Apr 29, 2026 · Updated 4 times
Summary
This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than current methods in 180 patients with advanced lung cancer, melanoma, or breast cancer. Participants will receive screening brain MRIs to compare diagnosis times. Early detection may offer more treatment options and help prevent neurological decline.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Zurich
Zurich, Canton of Zurich, 8091, Switzerland
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.